These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2509709)

  • 1. Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
    Wrobel J; Millen J; Sredy J; Dietrich A; Kelly JM; Gorham BJ; Sestanj K
    J Med Chem; 1989 Nov; 32(11):2493-500. PubMed ID: 2509709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
    Wrobel J; Millen J; Sredy J; Dietrich A; Gorham BJ; Malamas M; Kelly JM; Bauman JG; Harrison MC; Jones LR
    J Med Chem; 1991 Aug; 34(8):2504-20. PubMed ID: 1908522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer-assisted design and synthesis of novel aldose reductase inhibitors.
    Butera J; Bagli J; Doubleday W; Humber L; Treasurywala A; Loughney D; Sestanj K; Millen J; Sredy J
    J Med Chem; 1989 Apr; 32(4):757-65. PubMed ID: 2539477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.
    Sestanj K; Bellini F; Fung S; Abraham N; Treasurywala A; Humber L; Simard-Duquesne N; Dvornik D
    J Med Chem; 1984 Mar; 27(3):255-6. PubMed ID: 6422042
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N; Greselin E; Dubuc J; Dvornik D
    Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
    Kemper C; Dvornik D
    Proc Soc Exp Biol Med; 1986 Sep; 182(4):505-10. PubMed ID: 3090558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS; Hohman TC; Millen J
    J Med Chem; 1994 Jun; 37(13):2043-58. PubMed ID: 8027986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of macrophage chemotaxis and peripheral nerve regeneration in normal and hyperglycemic rats by the aldose reductase inhibitor Tolrestat.
    Calcutt NA; McMurray HF; Moorhouse DF; Bache M; Parthasarathy S; Powell HC; Mizisin AP
    Exp Neurol; 1994 Aug; 128(2):226-32. PubMed ID: 8076666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat.
    Robison WG; Kador PF; Akagi Y; Kinoshita JH; Gonzalez R; Dvornik D
    Diabetes; 1986 Mar; 35(3):295-9. PubMed ID: 3081393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy.
    Sredy J; Sawicki DR; Notvest RR
    J Diabet Complications; 1991; 5(1):42-7. PubMed ID: 1830318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of tolrestat, a novel aldose reductase inhibitor, in serum and tissues.
    Hicks DR; Kraml M
    Ther Drug Monit; 1984; 6(3):328-33. PubMed ID: 6438835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolrestat pharmacokinetics in rat peripheral nerve.
    Dvornik D; Millen J; Hicks DR; Kraml M
    J Diabetes Complications; 1994; 8(1):18-26. PubMed ID: 8167382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on antidiabetic agents. IX. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives: synthesis and biological activity.
    Tawada H; Sugiyama Y; Ikeda H; Yamamoto Y; Meguro K
    Chem Pharm Bull (Tokyo); 1990 May; 38(5):1238-45. PubMed ID: 2118427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spiro oxazolidinedione aldose reductase inhibitors.
    Schnur RC; Sarges R; Peterson MJ
    J Med Chem; 1982 Dec; 25(12):1451-4. PubMed ID: 6818344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
    Bank N; Coco M; Aynedjian HS
    Am J Physiol; 1989 Jun; 256(6 Pt 2):F994-9. PubMed ID: 2500030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase and retinal capillary basement membrane thickening.
    Robison WG; Nagata M; Kinoshita JH
    Exp Eye Res; 1988 Mar; 46(3):343-8. PubMed ID: 3127228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
    Wrobel J; Dietrich A; Woolson SA; Millen J; McCaleb M; Harrison MC; Hohman TC; Sredy J; Sullivan D
    J Med Chem; 1992 Nov; 35(24):4613-27. PubMed ID: 1469692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polyol pathway in retinal microangiopathy.
    Robison WG; Kinoshita JH; Kador PF
    Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat.
    McCaleb ML; Sredy J; Millen J; Ackerman DM; Dvornik D
    J Diabet Complications; 1988; 2(1):16-8. PubMed ID: 2968349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.